首页> 外文期刊>Breast Cancer Research and Treatment >A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors
【24h】

A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors

机译:加巴喷丁300与900 mg对比安慰剂对乳腺癌幸存者焦虑症状的随机对照双盲临床试验

获取原文
获取原文并翻译 | 示例
           

摘要

Gabapentin is used for the treatment of hot flashes and neuropathic pain in breast cancer survivors, and is commonly used off-label for the treatment of anxiety. Yet, clinical trial evidence to support the use of gabapentin for anxiety symptoms is lacking. In a randomized, double-blinded controlled trial we compared 300 mg gabapentin versus 900 mg gabapentin versus placebo. Subjects were 420 breast cancer patients who had completed all chemotherapy cycles. Anxiety traits and current (state) anxiety were measured using the Speilberger Strait-Trait Anxiety Inventory at baseline, 4 and 8 weeks. Pain was measured at baseline using a 10-point scale. Analyses included analysis of covariance and ordinary least squares regression. At 4 weeks, state anxiety change scores were significantly better for gabapentin 300 and 900 mg (p = 0.005) compared to placebo. The magnitude of improvement was proportional to baseline state anxiety. At 8 weeks, the anxiolytic effects of gabapentin compared to placebo persisted (p 0.005). We found no significant interactions. The lower dose (300 mg) was associated with the best treatment outcomes for all patients except those with the highest baseline anxiety. Given its similar pharmacology, efficacy in the treatment of hot flashes, and low cost, gabapentin may provide a low cost and parsimonious alternative treatment choice for breast cancer survivors presenting in primary care practices with anxiety symptoms. Gabapentin is effective for hot flashes, and, therefore, may provide therapeutic benefit for both anxiety and hot flashes at a generic drug price. For patients reluctant to take a controlled substance, such as a benzodiazepine, gabapentin may offer an alternative therapy. Similarly, patients with a history of substance use may benefit from gabapentin without risk of addiction or abuse. For cancer survivors experiencing both hot flashes and anxiety, gabapentin may provide a single effective treatment for both and is an alternative therapy for anxiety for patients unwilling to take a benzodiazepine or those with a history of substance use.
机译:加巴喷丁用于治疗乳腺癌幸存者的潮热和神经性疼痛,并且通常用于治疗焦虑症。然而,缺乏支持使用加巴喷丁治疗焦虑症状的临床试验证据。在一项随机,双盲对照试验中,我们将300 mg加巴喷丁与900 mg加巴喷丁与安慰剂进行了比较。受试者为420名完成所有化疗周期的乳腺癌患者。在基线,第4和第8周时,使用Speilberger Strait-Trait焦虑量表测量焦虑特质和当前(州)焦虑。使用10点量表在基线测量疼痛。分析包括协方差分析和普通最小二乘回归。与安慰剂相比,加巴喷丁300和900 mg在4周时的状态焦虑变化评分明显更好(p = 0.005)。改善程度与基线状态焦虑成正比。与安慰剂相比,在第8周,加巴喷丁的抗焦虑作用持续存在(p <0.005)。我们发现没有重大的相互作用。对于基线焦虑最高的患者,较低的剂量(300 mg)与最佳治疗效果相关。鉴于其相似的药理学,治疗潮热的功效以及低成本,加巴喷丁可以为存在焦虑症症状的基层医疗实践中的乳腺癌幸存者提供低成本和简约的替代治疗选择。加巴喷丁对潮热有效,因此可以以通用药物价格为焦虑症和潮热提供治疗益处。对于不愿服用受控物质(例如苯二氮卓类)的患者,加巴喷丁可能提供替代疗法。同样,有吸毒史的患者可以从加巴喷丁中获益,而不会上瘾或滥用。对于同时经历潮热和焦虑的癌症幸存者,加巴喷丁可以为两者提供单一有效的治疗方法,并且是不愿服用苯二氮卓类药物或有药物使用史的患者的另一种焦虑疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号